These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 362430)

  • 1. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents.
    Chedid L; Audibert F; Johnson AG
    Prog Allergy; 1978; 25():63-105. PubMed ID: 362430
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule.
    Chedid L; Carelli C; Audibert F
    J Reticuloendothel Soc; 1979 Dec; 26(Suppl):631-41. PubMed ID: 392087
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunoadjuvant effects of the synthetic muramyl-dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Heymer B; Finger H; Wirsing CH
    Z Immunitatsforsch Immunobiol; 1978 Oct; 155(1):87-92. PubMed ID: 706536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Past, present and future of the synthetic immunoadjuvant MDP and its analogs.
    Chedid L; Lederer E
    Biochem Pharmacol; 1978; 27(18):2183-6. PubMed ID: 365182
    [No Abstract]   [Full Text] [Related]  

  • 5. [Inhibition of IgE antibody formation by tubercle bacilli and muramyl peptide].
    Kishimoto T
    Kekkaku; 1980 Oct; 55(10):467-70. PubMed ID: 6785511
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunostimulant activities of a lipophilic muramyl dipeptide derivative and of desmuramyl peptidolipid analogs.
    Parant MA; Audibert FM; Chedid LA; Level MR; Lefrancier PL; Choay JP; Lederer E
    Infect Immun; 1980 Mar; 27(3):826-31. PubMed ID: 7380554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoadjuvant activity of synthetic N-acetyl muramyl dipeptide.
    Masek K; Zaoral M; Jezek J; Straka R
    Experientia; 1978 Oct; 34(10):1363-4. PubMed ID: 738426
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent advances concerning the use of muramyl dipeptide derivatives as vaccine potentiators.
    Audibert F; Chedid L
    Prog Clin Biol Res; 1980; 47():325-38. PubMed ID: 7010376
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.
    Krahenbuhl JL; Sharma SD; Ferraresi RW; Remington JS
    Infect Immun; 1981 Feb; 31(2):716-22. PubMed ID: 7216470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of antibodies to muramyl dipeptide in patients with tuberculosis or leprosy.
    Bahr GM; Modabber FZ; Rook GA; Mehrotra ML; Stanford JL; Chedid L
    Clin Exp Immunol; 1982 Jan; 47(1):53-8. PubMed ID: 6807589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP.
    Leclerc C; Juy D; Bourgeois E; Chedid L
    Cell Immunol; 1979 Jun; 45(1):199-206. PubMed ID: 313275
    [No Abstract]   [Full Text] [Related]  

  • 12. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
    Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of immunomodulatory properties of N-acetylmuramyl-L-alanyl-D-isoglutamine and N-acetylglucosaminyl-(beta 1----4)-N-acetylmuramyl-L-alanyl-D-isoglutamine.
    Dozmorov IM; Kuzin II; Lutsan NI; Lutsenko GV; Prokhorova AL; Sapozhnikov AM; Andronova TM; Ivanov VT
    Biomed Sci; 1991; 2(6):651-8. PubMed ID: 1841635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonspecific enhancement of host defenses against infection: experimental evidence of a new order of efficacy and safety.
    Polk HC; Calhoun JH; Lowrey LD; Blanchard SP; Brewer RJ; Adams ST; Chedid L
    Surgery; 1981 Aug; 90(2):376-80. PubMed ID: 7020139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of novel derivatives of muramyl dipeptide on the immune system].
    Kaliuzhin OV; Fuks BB; Bovin NV; Zemliakov AE; Chirva VIa
    Biull Eksp Biol Med; 1994 May; 117(5):510-3. PubMed ID: 9296705
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biological properties of synthetic glycopeptides stimulating immunogenesis and nonspecific resistance].
    Dzheksenbaev OSh
    Zh Mikrobiol Epidemiol Immunobiol; 1981; (8):13-8. PubMed ID: 7032159
    [No Abstract]   [Full Text] [Related]  

  • 17. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity.
    Chedid LA; Parant MA; Audibert FM; Riveau GJ; Parant FJ; Lederer E; Choay JP; Lefrancier PL
    Infect Immun; 1982 Feb; 35(2):417-24. PubMed ID: 7035362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fundamental studies to use the adjuvant activity of 6-o-acylmuramyldipeptides to potentiate cell and humoral immune responses for practical purposes].
    Tsujimoto M
    J Osaka Univ Dent Sch; 1981 Jun; 26(1):63-83. PubMed ID: 6945426
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier.
    Chedid L; Parant M; Parant F; Audibert F; Lefrancier F; Choay J; Sela M
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6557-61. PubMed ID: 293743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory and stimulatory effects of a synthetic glycopeptide (MDP) on the in vitro PFC response: factors affecting the response.
    Leclerc C; Juy D; Chedid L
    Cell Immunol; 1979 Feb; 42(2):336-43. PubMed ID: 371818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.